Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) nominated ESP-2001, a highly-specific allosteric ACLY inhibitor, as its preclinical development candidate for primary sclerosing cholangitis (PSC) on October 16, 2025. The company will begin IND-enabling studies with a goal to file an IND with the FDA in 2026 to start first-in-human trials. Preclinical models reportedly showed consistent reductions in markers of liver and bile duct injury, inflammation, and fibrosis. Esperion retains exclusive global development and commercialization rights and cites an estimated diagnosed PSC prevalence of ~76,000 in the U.S. and Europe and a potential market opportunity of over $1 billion annually. ESP-2001 may be eligible for Orphan Drug, Fast Track, and PRIME designations.
Esperion (Nasdaq: ESPR) priced an underwritten public offering of 30,000,000 common shares at $2.50 per share, with a 30-day underwriter option for up to 4,500,000 additional shares. Gross proceeds before fees are expected to be approximately $75.0 million, excluding any exercise of the option.
The offering is expected to close on or about October 9, 2025, subject to customary closing conditions, and is being sold pursuant to an effective shelf registration declared effective by the SEC on April 29, 2025. Piper Sandler and Cantor Fitzgerald are joint book‑running managers.
Esperion (Nasdaq: ESPR) announced on October 7, 2025 that it has commenced an underwritten public offering of its common stock, with all shares to be sold by the company.
The offering includes a 30‑day option for underwriters to buy up to an additional 15% of the shares. The offering is being made from an effective shelf registration declared effective by the SEC on April 29, 2025 (File No. 333-286631). Piper Sandler and Cantor Fitzgerald are joint book‑running managers.
Completion, size and terms are subject to market and other conditions; a preliminary prospectus supplement will be filed with the SEC and posted at www.sec.gov.
Esperion (NASDAQ: ESPR) announced a settlement with Dr. Reddy’s Laboratories resolving ANDA litigation over NEXLETOL and NEXLIZET. Under the agreement, Dr. Reddy’s will not market generic versions in the U.S. before April 19, 2040, except for customary limited exceptions. Esperion previously settled with Micro Labs, Hetero and Accord earlier in 2025. Esperion’s U.S. Patent No. 7,335,799 (bempedoic acid) expires December 2030; with this settlement there are no remaining challenges to that patent’s validity or infringement in the pending litigation. Other Esperion patents at issue expire March 2036 and June 2040. Litigation continues against several other ANDA filers, and there is no assurance those cases won’t permit earlier generic entry.
Esperion (NASDAQ: ESPR) announced that its partner Otsuka Pharmaceutical has received approval from Japanese regulators to market NEXLETOL for treating hypercholesterolemia and familial hypercholesterolemia in Japan. This approval marks NEXLETOL's entry into the third-largest global market for cardiovascular prevention.
The approval triggers milestone payments to Esperion under their partnership agreement with Otsuka, which includes tiered royalties of 15-30% on net sales in Japan and additional sales milestone payments. NEXLETOL, a non-statin LDL-C lowering therapy, is now approved across the U.S., Europe, and Japan, establishing a strong global presence for Esperion's cholesterol treatment.
Esperion (NASDAQ: ESPR) announced that bempedoic acid has received a prestigious Level 1a recommendation in the 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for Dyslipidaemias management.
The guidelines specifically recommend bempedoic acid as the only non-statin newly recommended treatment for LDL-C lowering and cardiovascular risk reduction. Key recommendations include using bempedoic acid for patients unable to take statins (Class I, Level A/B) and considering its addition to maximum statin doses with/without ezetimibe for high-risk patients (Class IIa, Level C).
This recognition supports Esperion's strategic development of oral triple combination therapies, aligning with the guidelines' emphasis on earlier, aggressive combination therapy. The company's portfolio includes NEXLETOL (bempedoic acid), NEXLIZET (bempedoic acid and ezetimibe), and upcoming triple combinations with atorvastatin or rosuvastatin.
Esperion (NASDAQ: ESPR), a commercial stage biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference on September 3 at 9:45 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 2:00 p.m. ET.
The company specializes in FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through partnerships and pipeline advancement.
Esperion (NASDAQ: ESPR) has announced the granting of 73,500 restricted stock units (RSUs) to 12 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on continued employment.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C. The company is also advancing its next-generation ATP citrate lyase inhibitor (ACLYi) program, leveraging new insights for developing highly potent and specific inhibitors.
Esperion (NASDAQ: ESPR) reported strong Q2 2025 financial results, with total revenue growing 12% year-over-year to $82.4 million. U.S. net product revenue increased 42% to $40.3 million, while total retail prescription equivalents grew 10% from Q1.
Key achievements include settlement agreements with three ANDA filers protecting NEXLETOL® until 2040, and the company's first-ever quarter of operating income ($15.0 million). Esperion expanded globally through partnerships in Japan, Europe, Canada, Israel, and Australia/New Zealand, with European royalty revenue increasing 30% sequentially to $13.6 million.
The company expects to achieve sustainable profitability beginning in Q1 2026 and maintains its 2025 operating expense guidance of $215-235 million.
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.